Clinical Trial Update: Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating iribrine plus tucidinostat in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor failure is listed with unknown statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hr-positive Advanced Breast Cancer

Drugs mentioned

• Tucidinostat (tucidinostat)
• iribrine (iribrine)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: HR Positive HER2 Negative Advanced Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN